Hervolution Therapeutics

Dark Genome Therapeutics Targeting the Diseases of Aging

[Hervolution Therapeutics @Hervolutiontx]

Today we welcome Dr. László B. Tankó to our Scientific Advisory Board. He most recently served as CMO of obesity drug startup Six Peaks Bio, which was acquired by Astra Zeneca in late 2025.

Welcome to the team, Dr. Tankó!

More: https://t.co/bgJ8dEKpHi

#Cardiometabolic

[Hervolution Therapeutics @Hervolutiontx]

We’re presenting at #SITC2025! Stop by Poster #646 to learn how we’re targeting the dark genome in solid tumors with IPT001.

#Immunotherapy #CancerResearch #Oncology

[Hervolution Therapeutics @Hervolutiontx]

Heading to Berlin for #ESMO2025 – looking forward to engaging with #oncology leaders and exploring the latest in cancer research and treatment innovation.
Get in touch if you’ll be attending!

#CancerResearch #MedicalOncology

[Hervolution Therapeutics @Hervolutiontx]

This week at the Aging Research & Drug Discovery Meeting, CSO Peter Holst presented a snapshot of HERVolution and our HERV-targeting approach to developing immunotherapies for age-related diseases like #cancer and #metabolic disorders.

Learn more: https://t.co/4w1QjFuPYU

[Hervolution Therapeutics @Hervolutiontx]

HERVolution CSO Peter Johannes Holst is heading to Amsterdam for the 8th Annual International Neoantigen Summit, June 24-26th.

Learn more about our approach: https://t.co/4w1QjFvnOs

We hope to see you there!

#Cancer #HERV

[Hervolution Therapeutics @Hervolutiontx]

CEO Robert Coleman and CSO Peter Johannes Holst are attending the Inaugural Dark Genome Target Discovery & Development Summit, held this week in Boston.

Learn more: https://t.co/4w1QjFvnOs

See you at the summit!

#Cancer #HERV #DarkGenome

[Hervolution Therapeutics @Hervolutiontx]

NEWS: Tine Gaziel, MD, PhD has been appointed as CMO. Dr. Gaziel will lead our clinical pipeline, including lead assets, IPT-001 and IPT-002—HERV-targeting immune therapies with potential to address diseases of aging like #cancer + #diabetes.

Learn more: https://t.co/1HhHWpBmv6

[Hervolution Therapeutics @Hervolutiontx]

Next week, our Director of Preclinical R&D Lasse Neukirch, PhD, will present data highlighting our platform’s ability to break immune tolerance against #DarkGenome antigens for therapeutic targeting of #SolidTumors at the Tumour Models Summit Nordics in Stockholm, Sweden!

[Hervolution Therapeutics @Hervolutiontx]

Proud to announce our $11.7M Series A financing.

Led by @SerumInstIndia + supported by @EU_EISMEA, funding will enable us to develop immunotherapies to target HERVs from the #DarkGenome to treat #cancer and #DiseasesOfAging.

https://t.co/0lScf2ZKB6

[Hervolution Therapeutics @Hervolutiontx]

Our latest article, "Cancer Vaccines: Recent Insights and Future Directions," has been published in the International Journal of Molecular Sciences as part of their Special Issue "Update on Immunotherapies for Cancer.

Read it here: https://t.co/lywHAo1Bw5

#IJMS #CancerVaccine

[Hervolution Therapeutics @Hervolutiontx]

CEO J. Robert Coleman, PhD, and CSO Peter Johannes Holst, MD, PhD, head to New York City this week to convene with global experts and researchers at the 3rd Annual Dark Genome Symposium, held November 20th-21st.

More: https://t.co/Kz8Ke5gGQC

#DarkGenomeSymposium #DarkGenome

[Hervolution Therapeutics @Hervolutiontx]

We're thrilled to welcome #ERV expert Enzo Tramontano to UCPH on March 8. His expertise in retroviruses will provide valuable insights and contribute to our understanding of this fascinating & emerging field. #JoinTheHervolution #HealthcareOfTomorrow

[Hervolution Therapeutics @Hervolutiontx]

Our founder & CSO, Peter Holst, will be presenting why HERVs are emerging as a cancer target at the Biologics World Nordics Conference in CPH. #JoinTheHervolution #HealthcareOfTomorrow

[Hervolution Therapeutics @Hervolutiontx]

At #JPM2024. Looking forward to valuable insights and meaningful collaborations with industry experts. Together, we're forging the path towards groundbreaking healthcare solutions. #JoinTheHervolution #HealthcareOfTomorrow

[Hervolution Therapeutics @Hervolutiontx]

Welcome Robert Coleman - our new CEO!
Robert's proven ability to navigate from early-stage innovation to clinical advancement will undoubtedly play a pivotal role in realizing the full potential of @Hervolutiontx 's pioneering #immunotherapies.
Read more: https://t.co/ySuDQP7Pco

[Hervolution Therapeutics @Hervolutiontx]

Looking forward to attending the #LSXInvestival Showcase and the #LSXEuropeanLifestarsAwards evening next week.

Get in touch if you'd like to meet the team and find out about @HERVOLUTION’s first-in-class immunotherapies targeting #HERV tumour antigens

[Hervolution Therapeutics @Hervolutiontx]

Our CSO, Dr Peter Holst, is presenting data at the SITC on 3rd November detailing our proprietary approach to breaking human immune system tolerance to human endogenous retroviral proteins #HERVs and using anti-HERV immunity to fight #cancer. #immunotherapy #sitc2023 @sitcancer

[Hervolution Therapeutics @Hervolutiontx]

We are thrilled to have been shortlisted as a finalist for Seed Finance Raise of the Year at the LSX European Lifestars Awards.

Best of luck to all the finalists!

#LSXEuropeanLifestarsAwards #HERV #SeedFinancing

[Hervolution Therapeutics @Hervolutiontx]

@HERVOLUTION is honoured to welcome Professor Robert Langer, co-founder of Moderna and MIT Professor, as Chair of its Scientific Advisory Board.
Read more here: https://t.co/pV68Pd7Mnb
#HERVs #immunotherapy

[Hervolution Therapeutics @Hervolutiontx]

Our recent rebrand to HERVOLUTION Therapeutics reflects our vision of developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs).
Visit our new website to find out more: https://t.co/4w1QjFvnOs
#HERVOLUTION #HERVs #immunotherapy